Journey Medical Corp (NASDAQ:DERM) — Market Cap & Net Worth
Market Cap & Net Worth: Journey Medical Corp (DERM)
Journey Medical Corp (NASDAQ:DERM) has a market capitalization of $136.73 Million ($136.73 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18098 globally and #4243 in its home market, demonstrating a -1.21% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Journey Medical Corp's stock price $7.36 by its total outstanding shares 21346446 (21.35 Million). Also see Journey Medical Corp balance sheet assets for a full breakdown of the balance sheet.
Journey Medical Corp Market Cap History: 2021 to 2026
Journey Medical Corp's market capitalization history from 2021 to 2026. Data shows change from $114.84 Million to $157.11 Million (-5.13% CAGR). Also see DERM operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
Journey Medical Corp is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.01% | #503 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1761 of 3165 |
Weight: Journey Medical Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Journey Medical Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Journey Medical Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Journey Medical Corp (DERM) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.66x
Journey Medical Corp's market cap is 2.66 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $114.84 Million | $63.13 Million | -$43.99 Million | 1.82x | N/A |
| 2022 | $40.99 Million | $73.67 Million | -$29.63 Million | 0.56x | N/A |
| 2023 | $122.96 Million | $79.18 Million | -$3.85 Million | 1.55x | N/A |
| 2024 | $83.46 Million | $56.13 Million | -$14.67 Million | 1.49x | N/A |
| 2025 | $164.58 Million | $61.86 Million | -$11.43 Million | 2.66x | N/A |
Competitor Companies of DERM by Market Capitalization
Companies near Journey Medical Corp in the global market cap rankings as of September 18, 2026. Review Journey Medical Corp (DERM) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Journey Medical Corp by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #520 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #619 globally with a market cap of $44.48 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #637 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Haleon plc (NYSE:HLN): Ranked #665 globally with a market cap of $41.22 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #520 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #619 | GALDERMA GROUP AG | NYSE:GALDY | $44.48 Billion | $38.15 |
| #637 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.10 |
| #665 | Haleon plc | NYSE:HLN | $41.22 Billion | $9.36 |
Journey Medical Corp Historical Marketcap From 2021 to 2026
Between 2021 and today, Journey Medical Corp's market cap moved from $114.84 Million to $ 157.11 Million, with a yearly change of -5.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $157.11 Million | -4.54% |
| 2025 | $164.58 Million | +97.19% |
| 2024 | $83.46 Million | -32.12% |
| 2023 | $122.96 Million | +200.00% |
| 2022 | $40.99 Million | -64.31% |
| 2021 | $114.84 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Journey Medical Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $136.73 Million USD |
| MoneyControl | $136.73 Million USD |
| MarketWatch | $136.73 Million USD |
| marketcap.company | $136.73 Million USD |
| Reuters | $136.73 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Journey Medical Corp
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat sev… Read more